Abbott Laboratories (ABT) Total Current Liabilities (2009 - 2026)

Abbott Laboratories has disclosed Total Current Liabilities across 18 years of filings, most recently posting $17.8 billion for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 32.55% year-over-year to $17.8 billion; the TTM figure through Jun 2026 stood at $17.8 billion (up 32.55% YoY), while the FY2025 annual figure was $16.5 billion, up 16.52% from the prior year.
• Total Current Liabilities came in at $17.8 billion for Q2 2026 at Abbott Laboratories, down from $18.4 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $18.4 billion in Q1 2026 to a low of $12.4 billion in Q2 2022.
• Average Total Current Liabilities over 5 years is $14.5 billion, with a median of $14.1 billion recorded in 2024.
• Year-over-year, Total Current Liabilities retreated 10.64% in 2023 and surged 41.32% in 2026.
• Over 5 years, Total Current Liabilities stood at $15.5 billion in 2022, then retreated by 10.64% to $13.8 billion in 2023, then increased by 2.28% to $14.2 billion in 2024, then climbed by 16.52% to $16.5 billion in 2025, then grew by 7.99% to $17.8 billion in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $17.8 billion in Q2 2026, $18.4 billion in Q1 2026, and $16.5 billion in Q4 2025.